Hester Biosciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5.00×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.37×	1.37×	1.56×	2.03×	1.53×
0.89×	0.89×	1.00×	1.31×	0.96×
2.8	2.8	5.6	12.7	13.2
56.1	56.1	70.0	109	78.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,054.00

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,747 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	5.00
Current Ratio	1.53	2.03	1.56	1.37	1.37
Quick Ratio	0.96	1.31	1.00	0.89	0.89
Cash, Equiv & ST Investments	13.2	12.7	5.6	2.8	2.8
Working Capital	78.9	108.8	70.0	56.1	56.1

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.